Furthermore, Azeliragon administered intraperitoneally at a dosage of 100 mcg/day, effectively reduces both syngeneic islet grafts and islet allografts in NOD and B6 mice. These mice models include NOD/LtJ mice with spontaneous diabetes receiving islets from young prediabetic NOD/LtJ mice, and diabetic B6 mice receiving islets from WT BALB/c mice, showcasing its potential in immunological applications beyond neurodegenerative disease^[3].

In experimental settings, Azeliragon (at a concentration of 4 nM for 16 hours) has been shown to inhibit the activation of wild type mouse (WT) T cells while not affecting RAGE-deficient mice (RAGE-/-). This treatment also significantly reduces the production of IFN-γ, indicating its potential impact on immune modulation in neurological contexts^[3].